Peter McL. Black
Peter McL. Black has a total of 226 co-authors. Here are the top co-authors by number of shared publications:
Jay S. Loeffler
2 shared publications- Aaron B. A. Shafer
Environmental and Life Sciences Graduate Program, Trent University, Peterborough, Ontario, Canada
1 shared publication - Abdulaziz Nasser Alagaili
KSU Mammals Research Chair, Department of Zoology, College of Science, King Saud University, Riyadh, Saudi Arabia
1 shared publication - Adam B. Salmon
Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, USA
1 shared publication - Adriana Arneson
Bioinformatics Interdepartmental Program, University of California, Los Angeles, CA, USA
1 shared publication - Ajoy Aloysius
Department of Biology, University of Kentucky, Lexington, KY 40508, USA
1 shared publication
Latest Publications
- Top Cited Papers
- 11 August 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 381 (6658) , eabq5693
DNA methylation networks underlying mammalian traits
Using DNA methylation profiles ( n = 15,456) from 348 mammalian species, we constructed phyloepigenetic trees that bear marked similarities to traditional phylogenetic ones. Using unsupervised clustering across all samples, we identified 55 distinct cytosine modules, of which 30 are related to traits such as maximum life span, adult weight, age, sex, and human mortality risk. Maximum life span is associated with methylation levels in HOXL subclass homeobox genes and developmental processes and is potentially regulated by pluripotency transcription factors. The methylation state of some modules responds to perturbations such as caloric restriction, ablation of growth hormone receptors, consumption of high-fat diets, and expression of Yamanaka factors. This study reveals an intertwined evolution of the genome and epigenome that mediates the biological characteristics and traits of different mammalian species.
- 11 August 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 381 (6658) , eabq5693
Top Cited PapersDNA methylation networks underlying mammalian traits
Using DNA methylation profiles ( n = 15,456) from 348 mammalian species, we constructed phyloepigenetic trees that bear marked similarities to traditional phylogenetic ones. Using unsupervised clustering across all samples, we identified 55 distinct cytosine modules, of which 30 are related to traits such as maximum life span, adult weight, age, sex, and human mortality risk. Maximum life span is associated with methylation levels in HOXL subclass homeobox genes and developmental processes and is potentially regulated by pluripotency transcription factors. The methylation state of some modules responds to perturbations such as caloric restriction, ablation of growth hormone receptors, consumption of high-fat diets, and expression of Yamanaka factors. This study reveals an intertwined evolution of the genome and epigenome that mediates the biological characteristics and traits of different mammalian species.
- Open Access
- 14 May 2021
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 2 (3) , 137
Maybe Next Year?
Remember just a few short months ago when we bid farewell to pandemic-ridden 2020 and ushered in 2021 with eager anticipation of returning to normal social activities, regular travel, and participation in-person in urologic meetings? While the vaccine effort plods along, more efficiently in some countries and regions than others (and certainly without any sense of global equity), you could well wonder if we will not at the end of this year find ourselves eagerly awaiting the same events for 2022. Coronamüde (corona-fatigued) rings loud for us all.
- 14 May 2021
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 2 (3) , 137
Open AccessMaybe Next Year?
Remember just a few short months ago when we bid farewell to pandemic-ridden 2020 and ushered in 2021 with eager anticipation of returning to normal social activities, regular travel, and participation in-person in urologic meetings? While the vaccine effort plods along, more efficiently in some countries and regions than others (and certainly without any sense of global equity), you could well wonder if we will not at the end of this year find ourselves eagerly awaiting the same events for 2022. Coronamüde (corona-fatigued) rings loud for us all.
- 16 April 2015
- Published by S. Karger AG
- Vol. 1, 75-82
Craniopharyngioma: Preliminary Results of Stereotactic Radiation Therapy
- 16 April 2015
- Published by S. Karger AG
- Vol. 1, 75-82
Craniopharyngioma: Preliminary Results of Stereotactic Radiation Therapy
- 1 July 2011
- Published by Elsevier in World Neurosurgery
- Vol. 76 (1-2) , 18-27
Neurosurgery Certification in Member Societies of the WFNS: Africa and the Middle East
- 1 July 2011
- Published by Elsevier in World Neurosurgery
- Vol. 76 (1-2) , 18-27
Neurosurgery Certification in Member Societies of the WFNS: Africa and the Middle East
- 1 April 2007
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 22 (2) , 243-249
Optimization of Equipment and Methodology for Whole Body Activity Retention Measurements in Children Undergoing Targeted Radionuclide Therapy
Accurate measurements of whole-body activity retention of patients during radionuclide therapy are essential for two reasons: First, they enable the correct radiation protection advice to be given and second, they permit the accurate determination of the absorbed whole-body dose delivered during therapy. This, in turn, allows treatment planning to be carried out for future radionuclide therapy on an individual patient basis, and also enables the investigation of the potential correlation of absorbed dose with treatment outcome in groups of patients. There are significant difficulties associated with taking whole-body retention measurements of children, especially when they are very young and/or unwell. It is essential to carry these out in a way that minimises disturbance to the child while still providing good quality data. To accomplish this, we have aimed to optimize the following aspects of the procedure: (i) the environment in which the measurements are performed; (ii) the equipment—which includes the recent installation of a specially designed whole-body activity monitoring system for these patients; and (iii) the methodology for calculating the absorbed dose. These improvements have allowed large numbers of accurate and reproducible whole-body measurements to be collected following patient administrations. This has enabled the identification of more phases of radionuclide excretion during therapy than had previously been observed. These data have been used for radiation protection advice and treatment planning. Two (2) patients were given multiple radionuclide treatments and we were able to compare the whole-body doses delivered.
- 1 April 2007
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 22 (2) , 243-249
Optimization of Equipment and Methodology for Whole Body Activity Retention Measurements in Children Undergoing Targeted Radionuclide Therapy
Accurate measurements of whole-body activity retention of patients during radionuclide therapy are essential for two reasons: First, they enable the correct radiation protection advice to be given and second, they permit the accurate determination of the absorbed whole-body dose delivered during therapy. This, in turn, allows treatment planning to be carried out for future radionuclide therapy on an individual patient basis, and also enables the investigation of the potential correlation of absorbed dose with treatment outcome in groups of patients. There are significant difficulties associated with taking whole-body retention measurements of children, especially when they are very young and/or unwell. It is essential to carry these out in a way that minimises disturbance to the child while still providing good quality data. To accomplish this, we have aimed to optimize the following aspects of the procedure: (i) the environment in which the measurements are performed; (ii) the equipment—which includes the recent installation of a specially designed whole-body activity monitoring system for these patients; and (iii) the methodology for calculating the absorbed dose. These improvements have allowed large numbers of accurate and reproducible whole-body measurements to be collected following patient administrations. This has enabled the identification of more phases of radionuclide excretion during therapy than had previously been observed. These data have been used for radiation protection advice and treatment planning. Two (2) patients were given multiple radionuclide treatments and we were able to compare the whole-body doses delivered.
- Open Access
- 1 January 2007
- Published by Elsevier in Neuropsychologia
- Vol. 45 (11) , 2543-2552
Diagnostic retrieval monitoring in patients with frontal lobe lesions: Further exploration of the distinctiveness heuristic
- 1 January 2007
- Published by Elsevier in Neuropsychologia
- Vol. 45 (11) , 2543-2552
Open AccessDiagnostic retrieval monitoring in patients with frontal lobe lesions: Further exploration of the distinctiveness heuristic
- 1 September 1997
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 139 (9) , 845-850
Apoptosis in astrocytic neoplasms
Apoptosis is a form of programmed cell death characterized by specific morphologic and biochemical properties. Tumorgenesis is the consequence not only of cell proliferation but also the loss of the ability to undergo apoptosis [2]. Bcl-2 is a protooncogene which has the ability to block apoptosis in many cell types. Astrocytic neoplasms are very aggressive tumors which many times fail to respond to surgery, radiation or chemotherapy. They frequently overexpress wild-type p53 which is associated with the expression of bcl-2, and thus they may have evolved a mechanism to subvert apoptosis and allow continued growth. We examined the apoptotic index in fifty-nine astrocytic tumors of various histological grades (Oncor ApopTag PlusIn Situ Detection Kit) and compared this with the level of bcl-2 expression. Low grade astrocytomas (0.21 ±0.05; range 0.0–0.9) and anaplastic astrocytomas (0.27 ±0.13; range 0.0–2.6) had significantly less apoptosis than glioblastomas (0.70 ± 0.13; range 0.0–2.1; Kruskal-Wallis test, P ≤0.01). In contrast, bcl-2 expression was similar in all grades of astrocytic tumors and did not correlate with the apoptotic index. Cells of low grade and anaplastic astrocytomas are less likely to undergo apoptosis; however, this does not seem to be a direct consequence of the regulation of bcl-2 expression. The difference in growth potential despite differences in apoptotic index is likely to be attributed to differences in mitotic not apoptotic activity.
- 1 September 1997
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 139 (9) , 845-850
Apoptosis in astrocytic neoplasms
Apoptosis is a form of programmed cell death characterized by specific morphologic and biochemical properties. Tumorgenesis is the consequence not only of cell proliferation but also the loss of the ability to undergo apoptosis [2]. Bcl-2 is a protooncogene which has the ability to block apoptosis in many cell types. Astrocytic neoplasms are very aggressive tumors which many times fail to respond to surgery, radiation or chemotherapy. They frequently overexpress wild-type p53 which is associated with the expression of bcl-2, and thus they may have evolved a mechanism to subvert apoptosis and allow continued growth. We examined the apoptotic index in fifty-nine astrocytic tumors of various histological grades (Oncor ApopTag PlusIn Situ Detection Kit) and compared this with the level of bcl-2 expression. Low grade astrocytomas (0.21 ±0.05; range 0.0–0.9) and anaplastic astrocytomas (0.27 ±0.13; range 0.0–2.6) had significantly less apoptosis than glioblastomas (0.70 ± 0.13; range 0.0–2.1; Kruskal-Wallis test, P ≤0.01). In contrast, bcl-2 expression was similar in all grades of astrocytic tumors and did not correlate with the apoptotic index. Cells of low grade and anaplastic astrocytomas are less likely to undergo apoptosis; however, this does not seem to be a direct consequence of the regulation of bcl-2 expression. The difference in growth potential despite differences in apoptotic index is likely to be attributed to differences in mitotic not apoptotic activity.
- 1 March 1996
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 84 (3) , 530-532
The radium bomb: Harvey Cushing and the interstitial irradiation of gliomas
✓ Harvey Cushing performed over 2000 operations on patients with brain tumors, including 832 for gliomas. He implanted radioactive radium needles, known as a “radium bomb,” in a small number of these patients. He was not impressed with the results and did not pursue this method of treatment in a serious way. The authors present here Cushing's little-known experience with brachytherapy and discuss the reasons for his lack of interest in this technique, despite his advocacy of radiotherapy for certain lesions. An interesting perspective is offered for contemporary neurosurgeons involved in the treatment of brain tumors with cranial irradiation.
- 1 March 1996
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 84 (3) , 530-532
The radium bomb: Harvey Cushing and the interstitial irradiation of gliomas
✓ Harvey Cushing performed over 2000 operations on patients with brain tumors, including 832 for gliomas. He implanted radioactive radium needles, known as a “radium bomb,” in a small number of these patients. He was not impressed with the results and did not pursue this method of treatment in a serious way. The authors present here Cushing's little-known experience with brachytherapy and discuss the reasons for his lack of interest in this technique, despite his advocacy of radiotherapy for certain lesions. An interesting perspective is offered for contemporary neurosurgeons involved in the treatment of brain tumors with cranial irradiation.
- 1 June 1994
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 34 (6) , 1110-1113
The Use of the Codman-Medos Programmable Hakim Valve in the Management of Patients with Hydrocephalus
CEREBROSPINAL FLUID SHUNTING is an important method of treating hydrocephalus. It sometimes has been difficult to achieve the optimum CSF pressure and ventricular size after shunt placement. Hydraulic and mechanical mismatching may occur, creating either overdrainage, as manifested by slit ventricle syndrome and/or subdural hygromas; or underdrainage, as manifested by a failure of the ventricles to change in size, with persistence of symptoms. A variable pressure valve (Codman-Medos Programmable Hakim valve system) has been developed to allow non-invasive increase or decrease in cerebrospinal fluid pressure in differentials of 10 mm of water within a range of 30–200 mm of water. This allows the neurosurgeon to adjust the pressure to the patient's particular clinical needs at any given moment. As part of a pilot study of the valve's safety, 13 patients in this center were treated with this programmable shunting system from October 1991 to January 1993. Twelve patients were over age 18 and one was younger than this. Six patients had previously been shunted with other valve systems, and the remaining seven had never been shunted before. The etiology of hydrocephalus included idiopathic normal pressure hydrocephalus (6 patients), aqueductal stenosis (3 patients), Chiari malformation (2 patients), meningitis (1 patient), and unknown etiology (1 patient). This paper describes the use of this valve in five illustrative cases; slit ventricle syndrome in an adult, chronic ventriculomegaly with aqueductal stenosis (2 cases), and idiopathic normal pressure hydrocephalus (2 cases). This programmable valve has been particularly useful in gradually decreasing ventricle size in idiopathic normal pressure hydrocephalus. In one case a subdural hematoma occurred as the pressure was diminished several months after surgery; it was treated by drainage and increasing the valve pressure for a period of several months without tying the shunt off. It has also been particularly useful in slit-ventricle syndrome management, and in gradually lessening the pressure in the huge ventricles of aqueductal stenosis. In this study several patients required a wide range of pressure changes during the period of observation, in some as much as 110 mm H2O. Several others were sensitive to changes as little as 10 mm H2O. All of the patients have required several pressure reprogrammings.
- 1 June 1994
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 34 (6) , 1110-1113
The Use of the Codman-Medos Programmable Hakim Valve in the Management of Patients with Hydrocephalus
CEREBROSPINAL FLUID SHUNTING is an important method of treating hydrocephalus. It sometimes has been difficult to achieve the optimum CSF pressure and ventricular size after shunt placement. Hydraulic and mechanical mismatching may occur, creating either overdrainage, as manifested by slit ventricle syndrome and/or subdural hygromas; or underdrainage, as manifested by a failure of the ventricles to change in size, with persistence of symptoms. A variable pressure valve (Codman-Medos Programmable Hakim valve system) has been developed to allow non-invasive increase or decrease in cerebrospinal fluid pressure in differentials of 10 mm of water within a range of 30–200 mm of water. This allows the neurosurgeon to adjust the pressure to the patient's particular clinical needs at any given moment. As part of a pilot study of the valve's safety, 13 patients in this center were treated with this programmable shunting system from October 1991 to January 1993. Twelve patients were over age 18 and one was younger than this. Six patients had previously been shunted with other valve systems, and the remaining seven had never been shunted before. The etiology of hydrocephalus included idiopathic normal pressure hydrocephalus (6 patients), aqueductal stenosis (3 patients), Chiari malformation (2 patients), meningitis (1 patient), and unknown etiology (1 patient). This paper describes the use of this valve in five illustrative cases; slit ventricle syndrome in an adult, chronic ventriculomegaly with aqueductal stenosis (2 cases), and idiopathic normal pressure hydrocephalus (2 cases). This programmable valve has been particularly useful in gradually decreasing ventricle size in idiopathic normal pressure hydrocephalus. In one case a subdural hematoma occurred as the pressure was diminished several months after surgery; it was treated by drainage and increasing the valve pressure for a period of several months without tying the shunt off. It has also been particularly useful in slit-ventricle syndrome management, and in gradually lessening the pressure in the huge ventricles of aqueductal stenosis. In this study several patients required a wide range of pressure changes during the period of observation, in some as much as 110 mm H2O. Several others were sensitive to changes as little as 10 mm H2O. All of the patients have required several pressure reprogrammings.